Reactions can appear anywhere
Evidence that some peptide formulations work does not validate peptides as a uniform class, and none of it speaks to injection
Alternative pharmacological options may be considered for patients who cannot continue GLP-1 therapy but require ongoing medication support
TB-500, a synthetic fragment derived from thymosin beta-4, has been studied for its role in cellular migration, cytoskeletal organization, angiogenesis, and tissue regeneration
Another randomized controlled trial in 2022 resulted in improved attention 50 minutes after dosing and in a dose dependent manner, the higher dose, the more response (100, 200, and 400 mg) (12)